文献速递肝病

纤维化标志物的纵向变化:监测MASLD中硬度/纤维化进展及预后结局

Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-24

该研究基于三个队列(VCTE-Prognosis队列n=10,203、配对肝活检队列n=1,145、温州真实世界队列n=41,105)分析动态FIB-4变化与肝硬度进展、纤维化进展及临床结局的关联。结果显示,FIB-4升高与硬度进展、纤维化进展及全因死亡、心血管事件和肝脏相关事件风险升高相关。结论认为动态FIB-4监测可追踪纤维化和硬度进展并预测临床结局。

要点

  • 低基线FIB-4组中,FIB-4升高者硬度进展风险较高(校正OR 2.36,P<.001)。
  • 高FIB-4组中,FIB-4升高者硬度进展风险较高(校正OR 3.42,P<.001)。
  • 动态FIB-4升高与全因死亡、心血管事件及肝脏相关事件风险升高相关(均P<.001)。

核心结论

  • 动态FIB-4监测可追踪MASLD患者的纤维化和硬度进展,并预测临床结局。

研究设计与样本

  • 分析三个队列:VCTE-Prognosis队列(n=10,203)用于硬度进展,配对肝活检队列(n=1,145)用于纤维化进展,温州真实世界队列(n=41,105)用于临床结局。

主要发现

  • VCTE-Prognosis队列中,低基线FIB-4组FIB-4升高者硬度进展风险较高(校正OR 2.36,P<.001);高FIB-4组FIB-4升高者硬度进展风险较高(校正OR 3.42,P<.001)。
  • 配对肝活检队列中,低FIB-4组FIB-4升高者纤维化进展更常见(校正OR 2.20,P=.004);高FIB-4组FIB-4升高者纤维化进展更常见(校正OR 3.68,P<.001)。
  • 温州真实世界队列中,动态FIB-4升高与全因死亡、心血管事件和肝脏相关事件风险升高相关(均P<.001)。

关键数值与推荐

  • FIB-4分为低值(<1.3)和高值(≥1.3)。
  • FIB-4升高定义为:低FIB-4组升高≥20%且升至≥1.3;高FIB-4组升高≥20%。
  • 硬度进展定义为肝脏硬度测量值增加;纤维化进展定义为纤维化分期增加1期。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fibrosis-4 Index (FIB-4) is a noninvasive tool for assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). However, its role of dynamic FIB-4 for assessing fibrosis progression and predicting clinical outcomes remains unclear. The aim of this study was to examine the association between changes in FIB-4 and changes in liver stiffness, fibrosis progression, and outcomes in MASLD. METHODS: Three cohorts were analyzed: VCTE-Prognosis cohort (n = 10,203) for stiffness progression, Paired Liver Biopsy cohort (n = 1,145) for fibrosis progression, and Wenzhou Real-World (WRW) cohort (n = 41,105) for clinical outcomes. Stiffness progression was defined as an increase in liver stiffness measurement, and fibrosis progression by a 1-stage increase. Outcomes included all-cause mortality, cardiovascular events, and liver-related events (LREs). FIB-4 was dichotomized into low (<1.3) and high (≥1.3). Increases were defined as ≥20% rise and to ≥1.3 in the low FIB-4 group, and ≥20% rise in the high FIB-4 group. RESULTS: In the VCTE-Prognosis cohort, stiffness progression was more likely with increasing vs stable FIB-4 (adjusted odds ratio [OR], 2.36; P < .001) in those with low baseline FIB-4. In the high FIB-4 group, stiffness progression rates increased from stable to increasing FIB-4 (adjusted OR, 3.42; P < .001). In the Paired Liver Biopsy cohort, fibrosis progression was more frequent with increasing FIB-4 (adjusted OR, 2.20; P = .004 in low FIB-4; adjusted OR, 3.68; P < .001 in high FIB-4). In the WRW cohort, an increase in dynamic FIB-4 was linked to higher risks for all-cause mortality, cardiovascular events, and LREs (all P < .001). CONCLUSIONS: Dynamic FIB-4 monitoring tracks fibrosis and stiffness progression and predicts clinical outcomes in MASLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Li YT, Kim SU, et al. Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD. Clin Gastroenterol Hepatol. 2025. PMID: 40714381. doi:10.1016/j.cgh.2025.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。